Patents by Inventor Maria L. Pras-Raves

Maria L. Pras-Raves has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Phenylpiperazine derivatives with a combination of partial dopamine-Dreceptor agonism and serotonin reuptake inhibition
    Patent number: 8101619
    Abstract: The invention relates to a group of novel phenylpiperazine derivatives with a dual mode of action: serotonin reuptake inhibition and partial agonism on dopamine-D2 receptors. The invention also relates to the use of a compound disclosed herein for the manufacture of a medicament giving a beneficial effect. The compounds have the general formula (1): wherein the symbols have the meanings given in the specification, and tautomers, stereoisomers and N-oxides thereof, as well as pharmacologically acceptable salts, hydrates and solvates of said compounds of formula (1) and its tautomers, stereoisomers and N-oxides.
    Type: Grant
    Filed: December 6, 2005
    Date of Patent: January 24, 2012
    Assignee: Solvay Pharmaceuticals B.V.
    Inventors: Roelof W. Feenstra, Axel Stoit, Jan-Willem Terpstra, Maria L. Pras-Raves, Andrew C. McCreary, Bernard J. Van Vliet, Mayke B. Hesselink, Cornelis G. Kruse, Gustaaf J. M. Van Scharrenburg
  • [1,2,4]-dithiazoli(di)ne derivatives, inducers of gluthathione-S-transferase and NADPH quinone oxido-reductase, for prophylaxis and treatment of adverse conditions associated with cytotoxicity in general and apoptosis in particular
    Patent number: 7678789
    Abstract: The present invention relates to 5-imino-5H-[1,2,4]-dithiazol-3-yl-amine and [1,2,4]-dithiazolidine-3,5-diylidene-diamine derivatives as inducers of gluthathione-S-transferase (GST) and NADPH quinone oxidoreductase (NQO), to methods for the preparation of these compounds and to novel intermediates useful for the synthesis of said [1,2,4]-dithiazoli(di)ne derivatives. The invention also relates to the use of a compound disclosed herein for the treatment of adverse conditions associated with cytotoxicity in general and apoptosis in particular. The invention relates to compounds of the general formula (I): wherein wherein the symbols have the meanings given in the specification.
    Type: Grant
    Filed: February 9, 2006
    Date of Patent: March 16, 2010
    Assignee: Solvay Pharmaceuticals B.V.
    Inventors: Roelof W. Feenstra, Hiskias G. Keizer, Maria L. Pras-Raves, Bernard J Van Vliet, Gustaaf J. M. Van Scharrenburg
  • 1,3,5-Triazine derivatives as ligands for human adenosine-A3 receptors
    Patent number: 7307079
    Abstract: The invention relates to a group of novel triazine derivatives which are ligands for human adenosine-A3 receptors, as well as to pharmaceutical compositions containing a pharmacologically active amount of at least one of these compounds as an active ingredient. The invention relates to compounds of the general formula (1) wherein Y represents a group of the general formula (A), (B) or (C) and all other symbols have the meanings as given in the description.
    Type: Grant
    Filed: May 30, 2003
    Date of Patent: December 11, 2007
    Assignees: Solvay Pharmaceuticals, B.V., Arqule, Inc.
    Inventors: Jacobus A.J. Den Hartog, Jan H. Reinders, Guustaaf J.M. Van Scharrenburg, Maria L. Pras-Raves, Gary R. Gustafson
  • Neurotensin active 2,3,diaryl-pyrazolidine derivatives
    Patent number: 7186741
    Abstract: The invention relates to a group of novel 2,3 diaryl-pyparazolidine derivatives having formula (1). The symbols used in formula (1) have the meanings given in the specification. The compounds have inhibiting activity on enzymes which degrade the neuropeptide neurotensin and can be used for the treatment of affections and diseases caused by disturbances of the neurotensin mediated transmission.
    Type: Grant
    Filed: March 17, 2003
    Date of Patent: March 6, 2007
    Assignee: Solvay Pharmaceuticals B.V.
    Inventors: Roelof W. Feenstra, Josephus H. M. Lange, Maria L. Pras-Raves, Cornelis G. Kruse, Herman H. van Stuivenberg, Tinka Tuinstra, Hiskias Keizer
  • Neurotensin active 2,3,diaryl-pyrazolidine derivatives
    Publication number: 20040242493
    Abstract: The invention relates to a group of novel 2,3 diaryl-pyparazolidine derivatives having formula (1). The symbols used in formula (1) have the meanings given in the specification. The compounds have inhibiting activity on enzymes which degrade the neuropeptide neurotensin and can be used for the treatment of affections and diseases caused by disturbances of the neurotensin mediated transmission.
    Type: Application
    Filed: March 23, 2004
    Publication date: December 2, 2004
    Inventors: Roelof W. Feenstra, Josephus H.M. Lange, Maria L. Pras-Raves, Cornelis G. Kruse, Herman H. van Stuivenberg, Tinka Tuinstra, Hiskias Keizer
  • 1,3,5-Triazine derivatives as ligands for human adenosine-A3 receptors
    Publication number: 20040038972
    Abstract: The invention relates to a group of novel triazine derivatives which are ligands for human adenosine-A3 receptors, as well as to pharmaceutical compositions containing a pharmacologically active amount of at least one of these compounds as an active ingredient.
    Type: Application
    Filed: May 30, 2003
    Publication date: February 26, 2004
    Inventors: Jacobus A.J. Den Hartog, Jan H. Reinders, Guustaaf J.M. Van Scharrenburg, Maria L. Pras-Raves, Gary R. Gustafson